Biological Malignancy Grading in Early-Stage Ovarian Carcinoma

References

• Auer G., Askensten U., Ahrens O. Cytophotometry. Hum Pathol 1989; 20: 518–27
   PubMed Web of Science ®Google Scholar
• Auer G., Caspersson T., Wallgren A. DNA-content and survival in mammary carcinoma. Anal Quant Cytol J 1980; 2: 161–5
   PubMedGoogle Scholar
• Sjövall K., Nilsson B., Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer 1994; 4: 333–6
   PubMed Web of Science ®Google Scholar
• Sjövall K., Silfverswärd C., Einhorn N. Ovarian cancer-the challenge of local tumor control and its impact on survival. Int J Radiat Oncol Biol Phys 1986; 12: 567–71
   PubMed Web of Science ®Google Scholar
• Einhorn N., Nilsson B., Sjövall K. Factors influencing survival in carcinoma of the ovary: Study from a well-defined Swedish population. Cancer 1985; 55: 2019–25
   PubMed Web of Science ®Google Scholar
• Young R. C. Initial therapy for early ovarian carcinoma. Cancer 1987; 60: 2042–9
   PubMed Web of Science ®Google Scholar
• Trimbos J. B., Schueler J. A., van der Burg M. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 1991; 67: 597–602
   PubMed Web of Science ®Google Scholar
• Kaern J. DNA ploidy in epithelial ovarian malignancies. Thesis. Norwegian Cancer Society, Oslo 1993
   Google Scholar
• Kalloniemi O-P, Punnonen R., Mattila J., Lehtinen M., Koivola T. Prognostic significance of DNA index, multi-ploidy, and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334–9
   PubMed Web of Science ®Google Scholar
• Baak J. P. A., Wisse-Brekelmans E. C. M., Uyterlinde A. M., Schipper N. W. Evaluation of the prognostic value of mor-phometric features and cellular DNA content in FIGO I ovarian cancer patients. Anal Quant Cytol Histol 1987; 9: 287–90
   PubMed Web of Science ®Google Scholar
• Klemi P. J., Joensuu H., Mäenpää J, Kilholma P. Influence of cellular DNA content on survival in ovarian carcinoma. Ob-stet Gynecol 1989; 74: 200–4
   PubMed Web of Science ®Google Scholar
• Haapasalo H., Atkin N. B., Collan Y., Pesonen E., Paljärvi L. Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: mutual relations. Anal Cell Pathol 1991; 3: 261–71
   PubMed Web of Science ®Google Scholar
• Erhardt K., Auer G., Björkholm E. Prognostic significance of nuclear DNA content in serous ovarian tumors. Cancer Res 1984; 44: 2198–202
   PubMed Web of Science ®Google Scholar
• Okamoto A., Sameshima Y., Yokoyama S. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991; 51: 1571–6
   PubMed Web of Science ®Google Scholar
• Kihana T., Tsuda H., Teshima S., Okada S., Matsura S., Hiro-Hashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA neuploidy. Jpn J Cancer Res 1992; 83: 978–84
   PubMedGoogle Scholar
• Sheridan E., Hancock B. W., Goyns M. H. High incidence of mutations of the p53 gene detected in ovarian tumors by the use of chemical mismatch cleavage. Cancer Lett 1993; 68: 83–9
   PubMed Web of Science ®Google Scholar
• Milner K. F. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128–32
   PubMed Web of Science ®Google Scholar
• Marks J. R., Davidoff A. M., Kerns B. J. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979–84
   PubMed Web of Science ®Google Scholar
• Teneriello M. G., Ebina M., Linnoila R. I. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 53: 3103–8
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Harper J. W., O'Connor P. M. WAF-1/CIP1 is induced in p53-mediated G(l) arrest and apoptosis. Cancer Res 1994; 54: 1169–74
   PubMed Web of Science ®Google Scholar
• Hartmann L. C., Podratz K. C., Keeney G. L. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64–9
   PubMed Web of Science ®Google Scholar
• Levesque M. A., Katsaros D., Yu H. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327–38
   Google Scholar
• Kohler M. F., Kerns B. J., Humphrey P. A., Marks J. R., Bast RC, Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993; 81: 643–50
   PubMed Web of Science ®Google Scholar
• Kupryjanczyk J., Thor A. D., Beauchamp R. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961–5
   PubMed Web of Science ®Google Scholar
• Hartmann L. C., Podratz K. C., Keeney G. L. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64–9
   PubMed Web of Science ®Google Scholar
• Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175–9
   PubMed Web of Science ®Google Scholar
• Kaufmann M., von Minckwitz G., Kühn W. Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 49–55
   PubMed Web of Science ®Google Scholar